•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its US partner Visus Therapeutics Inc., has published positive topline results from the pivotal Phase III BRIO-I trial. BRIO-I Trial Success and Regulatory MilestonesThe BRIO-I trial successfully met the pre-specified primary study endpoints that were agreed…
•
Shenzhen-based nanopore early cancer detection product developer, Meilitech Co., has reportedly raised tens of millions of renminbi in a Series A+ financing round, led exclusively by Autobio Diagnostics Co., Ltd (SHA: 603658). The funds raised will be directed towards technology research and development, product iteration, and end-implementation efforts. Company Background…
•
US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical Technology Co. The agreement grants Liuqiang exclusive rights to develop and commercialize Sable’s microneedle patch, which includes SBL-003 and SBL-004, in Greater China. The patch is designed for targeted aesthetic fat reduction through a process…
•
Japan-based optics giant Olympus Corp. is expanding its footprint in China with a planned investment of USD 40.6 million in a new factory located in Suzhou. The facility will specialize in the manufacturing of endoscope products, reflecting the company’s commitment to the Chinese market. Growing Significance of the Chinese Market…
•
Holox, a Beijing-based developer of healthcare management software, has reportedly secured tens of millions of renminbi in a Series A+ financing round. The funds raised will be directed towards the research and development of new products and the globalization of the company’s operations. Company Background and Pharmaceutical Safety ServicesFounded in…
•
Shanghai Kingstar Winning Software Science and Technology Co., Ltd, a leading provider of digitalization risk control solutions for medical and commercial insurance, has reportedly raised RMB 300 million (USD 43.39 million) in a Series C financing round. The round was led by China Taiping Insurance Group Company’s healthcare funds, with…
•
Beijing Luzhu Biotechnology Co., Ltd, a leading manufacturer of human vaccines and therapeutic biologics, is preparing for an initial public offering (IPO) of 10,386,000 shares at HKD 41.65 (USD 5.31) per share, which is expected to raise a total of HKD 433 million (USD 55.1 million). Company Background and Product…
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has received marketing approval from Bolivia’s State Agency of Drugs and Health Technologies (AGEMED) for its insulin glargine product, which comes in a pre-filled format. Insulin Glargine: A Long-Acting Insulin AnalogueInsulin glargine is a long-acting insulin…
•
China-based Rainmed Medical Limited has announced that it has received market approval from the National Medical Products Administration (NMPA) for its innovative coronary artery function measurement system, the caIMR system. Microcirculatory Resistance Index (IMR) and Its Clinical SignificanceThe microcirculatory resistance index (IMR) is a quantitative method used to evaluate the…
•
WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the first quarter of 2023, recording RMB 8.964 billion (USD 1.29 billion) in revenues, marking a 5.77% year-on-year (YOY) increase, and net profits of RMB 2.168 billion (USD 313.6 million), up 31.97% YOY. Client Expansion and…
•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status of two levornidazole specifications manufactured by Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), citing the need for intellectual property (IP) protection. Additionally, Anhui province has also paused the procurement of two levornidazole specifications made by…
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou Smart Nuclide Pharmaceutical Technology Company, a move focused on the development of radioactive drugs based on conjugate technology. Complementary Expertise in RadiopharmaceuticalsUnder the terms of the partnership, Tot Bio will offer a comprehensive antibody conjugate…
•
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of a two-dose schedule for its bivalent recombinant human papillomavirus (HPV) vaccine, Cervarix (types 16 and 18), targeting girls aged 9 to 14 in China. Cervarix’s Approval History and Expansion in ChinaCervarix was first approved in…
•
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary. This marks the beginning of a new treatment era for IgA nephropathy…
•
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire an 87.5% stake in US-based liquid embolic agent specialist BlackSwan Vascular Inc., for USD 37.5 million. This strategic move signifies Grand Pharma’s commitment to expanding its global presence in the medical device industry. BlackSwan Vascular…
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct two clinical studies. One study will investigate the combination of its drug candidate BL-B01D1 with osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small…
•
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB…
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has announced a strategic partnership with Qitan Tech, a Chengdu-based nanopore gene sequencer manufacturer. The collaboration aims to drive technology development, regulatory filings, localization, and industrialization of nanopore gene sequencers in the preimplantation genetic testing (PGT)…